The transcription factor C/EBP , a member of the CCAAT/enhancer-binding protein family, is highly expressed in the liver and in adipose tissue. The aim of this study was to determine if C/EBP is expressed in rat growth cartilage.
Introduction
Longitudinal bone growth is the result of proliferation and differentiation of chondrocytes in the growth plate. Growth plate chondrocytes are continuously produced from differentiating stem cells in the germinal zone of the growth plate. These chondrocytes subsequently undergo clonal expansion followed by growth arrest upon terminal differentiation. As a direct result of this process, the heterogeneous population of chondrocytes in growth cartilage is arranged into columnar formations (Kember 1971) . The continuous production of new cells in the upper layer of the growth plate, followed by clonal expansion and terminal differentiation of the underlying columnar chondrocytes, results in longitudinal bone growth.
The pivotal relationship between proliferation and differentiation has in many cases been shown to involve stage-specific transcription factors (Umek et al. 1991 , Olson 1992 . These nuclear proteins are influenced by hormones and growth factors, and growth-related gene expression is therefore placed under endocrine and paracrine control. The transcription factor C/EBP belongs to the CCAAT/enhancer-binding protein family and is important during hepatocyte differentiation as a regulator of several liver-specific genes (Friedman et al. 1989 , Dijk et al. 1992 , Nolten et al. 1994 . Furthermore, C/EBP is directly involved in the differentiation of preadipocytes into adipocytes (Samuelsson et al. 1991 , Umek et al. 1991 , Lin & Lane 1992 . Chondrocytes and adipocytes are both of mesenchymal origin. The common ancestry of these two cell lineages makes it conceivable that the chondrogenic differentiation programme may also involve members of the C/EBP family. However, expression of C/EBP has not previously been demonstrated in chondrocytes.
Several hormones are involved in the regulation of longitudinal bone growth. However, growth hormone (GH) is considered to be the most important hormone regulating this process (Cheek & Hill 1974) . Several studies, both in vivo and in vitro, have demonstrated that growth plate chondrocytes express functional GH receptors, confirming the notion that GH has direct effects on growth cartilage (Isaksson et al. 1982 , Madsen et al. 1983 , Edén et al. 1983 , Schlechter et al. 1986 , Barnard et al. 1988 , Nilsson et al. 1989 , 1990 , Werther et al. 1990 , Ohlsson et al. 1992a ,b, Bentham et al. 1992 . In a previous study, a panel of monoclonal antibodies was used to demonstrate the presence of GH receptors in the growth plate of the tibia in 20-to 50-day-old rabbits (Barnard et al. 1988) . GH receptor immunoreactivity was found in the germinal and proliferative layers of the growth plate, indicating that GH exerts its local effects on bone growth during the early stages of chondrogenesis.
The aim of the present study was to investigate whether the transcription factor C/EBP is expressed in growth plate chondrocytes and to see if it is regulated by GH.
Materials and Methods

Cell culture
Cultures of growth plate chondrocytes from the proximal tibia of 15-day-old rats (Sprague-Dawley; Alab Laboratory Services, Stockholm, Sweden) were established as described previously (Lindahl et al. 1986 ). Epiphyseal chondrocytes (7000/cm 2 ) were seeded in Dulbecco's modified Eagle's medium/F12 (Gibco, New York, NY, USA), supplemented with 10% fetal calf serum (Harlan Sera-Lab, Ltd, Crawley Down, Sussex, England), ascorbic acid (100 mg/l; Merck, Darmstadt, Germany), fungizone (0·5 mg/l; Gibco) and gentamicin sulphate (50 mg/l; Kibbutz Biological Industries, Beit Haemek, Israel).
Animals, surgical procedure and hormone treatment
Sprague-Dawley rats were maintained under standardised environmental conditions, i.e. 24-26 C, 50-60% relative humidity, artificial lighting from 0500 to 1900 h, with free access to water and food pellets. Rats were hypophysectomised by the standard parapharyngeal approach under combined ketamine (Ketalar; 67 mg/kg; Parke-Davis, Morris Plains, NJ, USA) and xylazine (Rompun; 13 mg/kg; Bayer, Leverkusen, West Germany) i.p. anaesthesia. Only male rats were used in the study. The rats were hypophysectomised at 35-40 days of life. Completeness of hypophysectomy was determined by recording weight gain for 1 week before hormonal therapy was started and by inspection of the sella region at autopsy.
Recombinant human GH (hGH) and insulin-like growth factor-I (IGF-I) were generously provided by Genentech Inc (South San Fransico, CA, USA). The hormones were dissolved in 0·9% saline and were given to hypophysectomised male rats at about 55-60 days of age. Human GH was given in three s.c. injections of 0·5 mg/kg at 12 h intervals. IGF-I was given in three s.c. injections of 0·65 mg/kg at 12 h intervals. Replacement therapy with cortisol acetate (Solucortef; Upjohn, Puurs, Belgium; 400 µg/kg per day) and thyroxine (L-T4; Sigma Chemical, St Louis, MO, USA; 10 µg/kg per day) was given to hypophysectomised rats in daily s.c. injections at 0800 h.
Western blotting
Crude protein extracts were obtained by resuspending cell pellets in a 1:1 dilution of 2 sample buffer (Novex, San Diego, CA, USA) and 100 m dithiothreitol, supplemented with protease inhibitors (aprotinin 2 µg/µl and phenylmethanesulphonyl fluoride 10 m). Cells were lysed by briefly sonicating the samples on ice. Proteins (20 µg) were loaded on to a Tris-glycine gel which was run at 190 V for 1 h and then blotted at 25 V for 2 h on to a polyvinylidene difluoride membrane (Novex). The membrane was blocked overnight in Tris-buffered saline (TBS; 0·01  Tris-HCl, pH 7·6, 0·15  NaCl)-0·5% Tween with 10% dried milk powder (Semper, Stockholm, Sweden) and then incubated at room temperature for 1 h with a rabbit polyclonal antibody to C/EBP (Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted 1:100 in TBS-0·5% Tween with 1% dried milk powder. The membrane was washed (2 7 min) in TBS-0·5% Tween and then incubated with a secondary antibody (horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG; Amersham International, Amersham, Bucks, UK) for 1 h at room temperature, diluted 1:5000 in the same solution as the primary antibody. The membrane was finally washed (3 7 min) in TBS-0·5% Tween. HRP conjugates were visualised with an ECL kit (Amersham) according to the manufacturer's instructions.
Probe synthesis
The p4Zm C/EBP plasmid (Samuelsson et al. 1991) was cleaved with EcoRI and HindIII. The resulting 800 bp cDNA fragment was separated from vector DNA on a 1% agarose gel and isolated by DEAE-membrane elution. For Northern blots, the purified cDNA was labelled with [ 32 P]dCTP using a nick-translation kit (Promega, Madison, WI, USA).
The same cDNA template was used for the RNase protection/solution hybridisation assay. The antisense [ 35 S] UTP-labelled probe was generated by in vitro transcription using T7 polymerase (Boehringer-Mannheim, Mannheim, Germany) while the sense probe was synthesised by using SP6 polymerase (Boehringer-Mannheim). Template DNA was removed by digestion with DNase I (Promega).
Northern blotting
Total RNA was prepared from liver by the acidguanidinium thiocyanate method (Chomczynski & Sacchi 1987) . Total RNA (20 µg) was electrophoresed through an agarose (1%)/formaldehyde (2·2 ) gel with ethidium bromide added. The RNA was transferred to a Hybond-N membrane (Amersham) by capillary blotting and baked at 80 C for 2 h. The membrane was prehybridised for 24 h at 45 C in a buffer consisting of 50% formamide, 5 SSC, 2·5 Denhardt's solution, 5 m Na 2 HPO 4 , 0·1% SDS, 250 µg/ml salmon sperm DNA and 250 µg/ml yeast tRNA. The membrane was hybridised for 24 h at 45 C in the prehybridisation buffer with the [ 32 P]dCTP-labelled probe added and washed three times in 2 SSC-0·1% SDS at 50 C.
Solution hybridisation assay
C/EBP mRNA was quantified with a RNase protection/solution hybridisation assay. Total nucleic acids for the RNase protection/solution hybridisation assay were prepared by homogenising liver tissue, rib growth plates or harvested primary epiphyseal chondrocytes with a polytron in buffer containing 1% (w/v) SDS, 20 mmol/l Tris-HCl (pH 7·5) and 4 mmol/l EDTA. The homogenised cells were then digested by overnight proteinase K treatment, and the total nucleic acids were prepared by subsequent phenol-chloroform extraction (Durnam & Palmiter 1983) . The RNase protection/solution hybridisation assay was then carried out as described elsewhere (Mathews et al. 1986 ). The results were correlated with the DNA content. DNA analysis was performed as described elsewhere (Labarca & Paigen 1980) .
Immunohistochemistry
Rat tibia was fixed overnight in a solution of 3·7% formaldehyde in PBS. The tissue was decalcified, embedded in paraffin and mounted on to a cryostat. Sections (10 µm) were cut and collected on slides (Superfrost/+, Menzel-Glöser, Braunschweig, Germany). Slides were treated (3 10 min) with xylene for removal of the paraffin and thereafter hydrated in a descending series of ethanol baths. Hydrated sections were incubated for 30 min with TBS containing 10% goat serum (Amersham). A primary polyclonal antibody to C/EBP , a monoclonal antibody to the GH receptor (Mab263; AGEN Biomedical Ltd, Acacia Ridge, Qld, Australia) and a monoclonal antibody to desmin (Dako, Copenhagen, Denmark) were diluted 1:10 in TBS with 1% goat serum. The diluted primary antibody was applied to the slides, which were incubated overnight at 4 C. After incubation with the primary antibody, the slides were rinsed in TBS. Secondary antibodies (HRP-conjugated donkey antirabbit or donkey anti-mouse IgG; Amersham) were diluted 1:50 in TBS and added to the slides, which were incubated at room temperature for 1 h. After being washed in TBS (2 10 min), the HRP conjugates were visualised with diaminobenzidine (Dako).
Statistical procedures
Values are given as means ... The statistical significance of differences between means was calculated by ANOVA followed by Student-Neuman-Keul's multiple range test.
Results
Western blotting with a polyclonal antibody specific for C/EBP was used to demonstrate the expression of the C/EBP protein in monolayer-cultured primary growth plate chondrocytes (Fig. 1A) . The two isoforms of C/EBP (p42 and p30) were detected at all stages of confluence studied. The levels of both isoforms were increased in postconfluent cells (25 days of culturing) compared with subconfluent cells (cultured for 2 days; 2042 336% (p42) and 465 80% (p30) of subconfluent cells; Fig. 1B ).
The expression of the C/EBP mRNA transcript was detected with an RNase protection/solution hybridisation assay. The specificity of the probe used was verified with a Northern blot demonstrating, as expected, a specific band at 2·7 kb ( Fig. 2A) . The levels of the C/EBP mRNA transcript in rib cartilage were approximately five times lower than in liver (Fig. 2B) . Monolayer-cultured chondrocytes expressed twice as much C/EBP mRNA as rib cartilage after 7 days of culture. As for the protein data, the mRNA levels had increased with increasing growth density after 3 weeks in culture (Fig. 2B) .
Immunohistochemical analysis of sections of the proximal part of the tibia from 20-day-old rats demonstrates that C/EBP immunoreactivity is present in the perichondrial ring (Fig. 3A, B and D) , in the germinal layer of the growth plate (Fig. 3E , F and G) and on the surface of the articular cartilage ( Fig. 3I and J) . No immunoreactivity was found in the proliferative or hypertrophic cell layers of the growth plate, except in the regions proximal to the perichondrial ring, where a trace of C/EBP immunoreactivity, which decreases with the distance from the perichondrium, is present ( Fig. 3B  and D) .
The pattern of GH-receptor immunoreactivity in the tibia (Fig. 4) is similar to that of C/EBP (Fig. 3) . Perichondrial cells stain heavily (Fig. 4A, B and D) . Decreasing levels of immunoreactivity can also be detected in growth cartilage adjacent to the perichondrial ring, resembling the pattern described for C/EBP . In addition, cells in the germinal layer (Fig. 4E ) and on the surface of the articular cartilage (Fig. 4G) are positively stained.To verify the results, a series of control reactions were performed. On C/EBP slides, non-immune rabbit serum (Amersham; Fig. 3C , H and K), omission of primary antibody (data not shown) or preabsorption of C/EBP antibody with a control peptide (Santa Cruz; sc61P; data not shown) led to abolished immunoreactivity.
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GH-receptor controls included omission of primary antibody (data not shown) and the use of a non-immune monoclonal mouse IgG as the primary antibody (Fig. 4C,  F and H) . In both cases immunoreactivity was abolished in the treated sections. A monoclonal desmin antibody was also used as a control and produced a characteristic cross-striated immunoreactivity in skeletal muscle surrounding the tibia, but not in the perichondrium or the growth plate ( Fig. 4I; Fig. 4J is a control on the same slide where a non-immune monoclonal mouse IgG was used as a primary antibody).
The colocalised expression of C/EBP with the GH receptor indicates that C/EBP may be regulated by GH in the rat growth plate. To study if the levels of C/EBP mRNA were regulated by GH, or by other pituitary hormones, the C/EBP mRNA levels in rib growth cartilage from hypophysectomised rats were compared with those in normal rats. Hypophysectomy decreased C/EBP mRNA levels (69 8% of control; Fig. 5 ). Treatment of hypophysectomised rats with GH (3 h) or IGF-I (1·5 h) did not counteract the effect of hypophysectomy.
Discussion
This study shows, for the first time, that the transcription factor C/EBP is expressed in a growth-related manner in cultured growth plate chondrocytes, as well as in vivo in the rat growth plate. In monolayer-cultured chondrocytes, a marked increase in the C/EBP transcript and protein is seen with increasing cell density. This is similar to the regulation in differentiating preadipocytes and hepatocytes. The levels of the C/EBP transcript found in liver are approximately five times higher than the levels found in the rib cartilage (Fig. 2) . However, in monolayercultured chondrocytes the levels are higher and range between 40 and 60% of the levels found in liver.
Earlier studies, in vivo and in vitro, indicated that GH induces differentiation of prechondrocytes, resulting in a concomitant clonal expansion (Morikawa et al. 1982 , Isaksson et al. 1985 , Ohlsson et al. 1992a . GH-receptor immunoreactivity was, in the present study, found in the perichondrium and in the germinal layer, which supports the notion that GH stimulates the differentiation of prechondrocytes. The location of GH-receptor immunoreactivity is similar to the distribution described previously (Barnard et al. 1988) . However, in the previous study, GH-receptor immunoreactivity was also reported to be present in the proliferative layer of the growth plate. There could be several explanations, including species and age differences, for the fact that GH-receptor immunoreactivity was found in the proliferative layer of the growth plate previously. Nevertheless, the GH-receptor distribution described here, in the germinal layer of the rat growth plate, is supported by two previous in vivo studies demonstrating that GH treatment increases the mitotic activity in the germinal layer of hypophysectomised rats (Ohlsson et al. 1992b , Hunziker et al. 1994 . Furthermore, several in vitro studies using growth plate chondrocytes indicate that GH interacts with prechondrocytes: GH binding is localised to chondrogenic precursor cells in cultures of growth plate chondrocytes (Bentham et al. 1992) , and GH promotes colony formation of prechondrocytes (Ohlsson et al. 1994 , Lindahl et al. 1987 .
Interestingly, in vivo, C/EBP immunoreactivity was colocalised with GH-receptor immunoreactivity, indicating that the expression of C/EBP is also restricted to the early stages of chondrogenesis. It is apparent from the immunolocalization that proliferative chondrocytes do not express C/EBP , and immunoreactivity is accordingly not seen in the central parts of the growth plate. However, adjacent to the perichondrial ring, C/EBPimmunoreactivity can be seen in mature chondrocytes. This immunoreactivity gradually decreases with increasing distance from the perichondrium. C/EBP expression and proliferation have been reported to be mutually exclusive events during adipogenesis, so the absence of C/EBP protein during the later stages of chondrogenesis, in vivo, could be due to the fact that differentiated chondrocytes undergo clonal expansion in the proliferative zone of the growth plate. Based on these observations, we propose that C/EBP is a marker of early chondrogenic development and that the expression pattern of C/EBP in vitro reflects the well-known fact that chondrocytes in monolayer culture do not differentiate. The increased levels of C/EBP , in vitro, in confluent cells, compared with the subconfluent stage, are probably not the result of differentiation, as described in preadipocytes, but rather the result of contact inhibition and growth arrest in postconfluent cultures. This notion is further supported by the fact that C/EBP in vivo is predominantly expressed in regions of the proximal tibia where GH-responsive and slowly dividing chondrogenic stem cells are located (Ohlsson et al. 1992b) .
A density-dependent increase in the number of GH receptors on monolayer-cultured chondrocytes which resembles the increase in C/EBP protein seen in the present study has previously been described (Nilsson et al 1989) . Our observation that C/EBP and the GH receptor display similar expression patterns in vitro and that these two proteins are colocalised in vivo raised the question whether C/EBP is a direct or indirect target for GH in the growth plate. We used hypophysectomised rats as a model to study the levels of C/EBP mRNA in rib cartilage in the absence of pituitary hormones. Hypophysectomy resulted in a decrease in the C/EBP mRNA levels, demonstrating that C/EBP mRNA levels are regulated by pituitary factors. This decrease could not be counteracted by GH or IGF-I treatment, indicating that other pituitary factors rather than GH regulate the levels of C/EBP mRNA. However, since the effect of GH treatment on C/EBP mRNA levels was not studied over an extended period of time, we cannot fully exclude the possibility that C/EBP mRNA levels are altered after prolonged exposure of rats to GH. It should also be noted that the hypophysectomised rats used in this study were treated with thyroid hormone and cortisone but not with sex steroids. It is therefore possible that the decrease in C/EBP mRNA after hypophysectomy results from the absence of sex steroids. Members of the C/EBP family readily undergo heterotypic dimerisation with each other and with members of other transcription factor families (Lamb & McKnight 1991 , Hsu et al. 1994 . In a recent report it was demonstrated that short-term treatment of 3T3-F442A preadipocytes with GH increases the levels of C/EBP and C/EBP (Clarkson et al. 1995) . It is conceivable that C/EBP by heterodimerisation with these and other transcription factors could provide a convergent pathway by which other hormones and growth factors modulate the GH response.
In conclusion, C/EBP immunoreactivity is abundant in prechondrocytes of the growth plate, indicating a role for C/EBP in the regulation of cellular events during chondrogenesis. Furthermore, C/EBP is colocalised with the GH receptor in the rat tibia. C/EBP mRNA levels were decreased after hypophysectomy but were not altered by GH treatment, indicating that C/EBP is subjected to regulation by other pituitary factors rather than GH. A functional role for C/EBP during chondrogenesis still remains to be demonstrated. 
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